The aim of the study is to investigate if M5049 intervention at a critical point in the course of COVID-19 disease may prevent or ameliorate the hyper-inflammatory response in patients with COVID-19 pneumonia and prevent progression to 'cytokine storm'. Successful intervention with the investigational drug may reduce life-threatening complications of COVID-19, including severe respiratory symptoms that often necessitate further medical interventions such as mechanical ventilation.
"At Merck, we have a clear priority to identify potential solutions across the full spectrum of the COVID-19 pandemic, including prevention, symptom management, severe infection and recovery," said Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare. "With M5049, we aim to study a novel approach to treating severe complications of COVID-19 that we hypothesize could translate to other single-stranded RNA viruses including other coronaviruses."
M5049 will be investigated in a randomized, placebo-controlled study at sites in the United States and Brazil. In addition to standard of care, which may include antiviral treatments, subjects will receive one of two doses of M5049 or placebo with the intent of comparing M5049 to placebo based on patient outcomes. Approximately 150 subjects will be randomized into one of the three treatment arms. In addition to the FDA, Merck is working with other global health authorities and investigators to accelerate clinical development to meet the critical need presented by the current global pandemic and expects results from the Phase II study around the end of 2020.
M5049 was discovered in-house at Merck and recently completed a Phase I study in healthy volunteers. The company is evaluating M5049 in immunology indications in addition to a potential therapeutic intervention against COVID-19.
This Phase II study complements the existing response from Merck to the COVID-19 pandemic, which also includes in-kind contributions, product donations, resources, and expertise in consortia and partnerships aimed at fighting this COVID-19 pandemic. Merck is dedicated to serving patients, scientists and customers around the globe - for more information on the response, please click here.
About MerckMerck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - the company is everywhere. In 2019, Merck generated sales of € 16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.